| 前收市價 | 234.80 |
| 開市 | 235.10 |
| 買盤 | 237.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 234.00 - 237.80 |
| 52 週波幅 | 212.90 - 293.55 |
| 成交量 | |
| 平均成交量 | 1,498,885 |
| 市值 | 191.277B |
| Beta 值 (5 年，每月) | 0.16 |
| 市盈率 (最近 12 個月) | 16.56 |
| 每股盈利 (最近 12 個月) | 14.32 |
| 業績公佈日 | 2024年7月25日 |
| 遠期股息及收益率 | 9.60 (4.05%) |
| 除息日 | 2024年3月14日 |
| 1 年預測目標價 | 273.94 |
ZacksThe Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Barrons.comDow Hitting 40,000 Is Good but Look Here for Where Markets Are Headed, and 5 Other Things to Know Today.
Reddit content is coming to OpenAI’s chatbot, Roche’s weight-loss drug impresses analysts in early-stage trials, and other news to start your day.
